KVK-Tech, Inc. Issues Voluntary Nationwide Recall of One Lot of Betaxolol Tablets, USP 10 mg (Batch Number: 17853A) as a Precautionary Measure Due to a Single Foreign Tablet
September 29, 2023FDA Approves Technegas® (Technetium Tc 99-m Labeled Carbon) Radioactive Diagnostic Agent
October 2, 2023October 2, 2023 - Novo Nordisk announced the U.S. Food and Drug Administration has approved Rivfloza TM (nedosiran) injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid interference (RNAi) therapy, to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
Primary hyperoxaluria (PH) is a rare genetic disease that causes overproduction of oxalate by the liver that is estimated to affect 1 in 38,600 individuals worldwide. PH1 is the most clinically prevalent (roughly ~80% of PH patients) and severe of the three subtypes of PH. PH1 is a progressive metabolic disorder that primarily affects the kidneys and can lead to progressive kidney damage. In the U.S., it is estimated that over 2,000 people are living with PH1.
Rivfloza TM , the first RNAi therapeutic by Novo Nordisk, was developed using the proprietary GalXC TM RNAi technology platform. Rivfloza TM is designed to inhibit the expression of liver enzyme lactate dehydrogenase, a liver enzyme that catalyzes the final common step in the glyoxylate metabolism pathway which leads to the oxalate overproduction in patients with PH1.
Rivfloza TM was developed by Dicerna Pharmaceuticals, Inc. which was acquired by Novo Nordisk in 2021. Novo Nordisk plans to make Rivfloza TM available for eligible patients in early 2024.
The most common side effects of Rivfloza TM include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection .